Watchlist Price Alert

Lucid Diagnostics Inc. (LUCD)

NASDAQ: LUCD · Real-Time Price · USD

1.52

0.00 (0.00%)

At close: May 29, 2025, 3:59 PM

1.50

-1.64%

After-hours: May 29, 2025, 06:57 PM EDT

0.00% (1D)

Bid	1.5
Market Cap	164.99M
Revenue (ttm)	831.35M
Net Income (ttm)	-36.05B
EPS (ttm)	-1.17
PE Ratio (ttm)	-1.3
Forward PE	-4.77
Analyst	Buy

Ask	1.55
Volume	821,132
Avg. Volume (20D)	1,156,372
Open	1.53
Previous Close	1.52
Day's Range	1.50 - 1.58
52-Week Range	0.68 - 1.80
Beta	1.28

About LUCD

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol LUCD

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for LUCD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

-24.24%

Lucid Dagnositcs shares are trading lower followin... Unlock content with Pro Subscription

1 month ago

+1.85%

Lucid Diagnostics shares are trading lower after the company announced a proposed public offering of common stock.

News

2 weeks ago · seekingalpha.com

Lucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call Transcript

Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q1 2025 Business Update Conference Call May 14, 2025 8:30 AM ET Company Participants Matt Riley – Senior Director-Investor Relations Lishan Aklog – Chairman and C...

2 weeks ago · zacks.com

Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates

Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.21 per share a year ago.

3 weeks ago · zacks.com

Will Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should Know

Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · benzinga.com

Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst

According to Needham, Lucid Diagnostics Inc. LUCD is likely to receive approval for EsoGuard testing-related Medicare reimbursement, which would boost testing volumes.

2 months ago · seekingalpha.com

Lucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call Transcript

Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director, Investor Relations Lishan Aklog - Chairman & Chief E...

2 months ago · zacks.com

Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Lags Revenue Estimates

Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.23 per share a year ago.